Please login to the form below
43
Revenue 2017Perjeta
The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Perjeta was produced by Roche.
Roche in "unprecedented" launch period for new medicines
The star in Roche's show was once again its trio of HER2-positive breast cancer drugs - Herceptin (trastuzumab), Perjeta (pertuzumab) and Kadcyla (trastuzumab emtansine) - whose sales increased 9% to ... 12bn francs, driven mainly by a 31% growth for
Roche's melanoma combo "too expensive" for NHS use, says NICE
NICE arrived at a similar conclusion when it published a review of breast cancer drugs Perjeta (pertuzumab) in May and Kadcyla (trastuzumab-emtansine) at the end of last year.
Roche says Tecentriq "off to a good start"
Strong gains for Perjeta (pertuzumab) and Kadcyla (ado-trastuzumab emtansine) reinforced a 5% increase for HER2 stalwart Herceptin (trastuzumab) to 3.4bn francs.
NICE rejects Roche's breast cancer drug Perjeta
Perjeta is used alongside Herceptin or docetaxel to reduce the volume of breast tumours before surgery, making it easier to carry out the operation. ... The preliminary recommendations are open for comment until June 13, and any patient already on
Cancer drugs help Roche beat expectations in first quarter
Co. Among Roche's newer products, breast cancer drug Perjeta (pertuzumab) grew 33% to CHF439m thanks to increased use in combination with Herceptin in HER2-positive breast cancer, while arthritis medication
[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
- Relief Therapeutics’ COVID-19 drug shows positive results ahead of trial readout
- GSK chief exec ‘optimistic’ COVID-19 vaccine could be available next year
- Pfizer CEO says COVID-19 vaccine efficacy data could come ‘soon’
- FDA sets November date for expert panel review of Biogen’s aducanumab
- Novartis weathers the COVID-19 storm in Q3, lifts outlook
- FDA approves Gilead’s remdesivir for hospitalised COVID-19 patients
- The science of the deal
- Live Webinar: Overcoming Behavioral Health Access Limitations Through Telemedicine
- Pfizer CEO says COVID-19 vaccine efficacy data could come ‘soon’
- Lilly’s Q3 earnings slump on COVID-19 development costs, pricing pressures
- Keytruda growth helps Merck to offset COVID-19 impact in Q3
- Celebrating the hard work and dedication of our wonderful Talent Manager
PMHub
11 London
11 London is a strategic and creative agency working in the fields of health and humanity – complex areas, but...
Latest intelligence
- The science of the deal
- Business development is more like child-raising than you might think...
- The other side of … rheumatoid arthritis
- For Georgie, patient activation fuelled her motivation to find life without pain. So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed......
- How to lessen site burden with a targeted patient recruitment strategy
- Picture this: you’ve created your patient recruitment strategy and you find more and more patients are undertaking the pre-screening, you probably think – success! But then you find out, getting...
Quick links
Infographics
